1. Home
  2. VYGR vs UIS Comparison

VYGR vs UIS Comparison

Compare VYGR & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.48

Market Cap

203.6M

Sector

Health Care

ML Signal

HOLD

Logo Unisys Corporation New

UIS

Unisys Corporation New

HOLD

Current Price

$3.89

Market Cap

220.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYGR
UIS
Founded
2013
1942
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
203.6M
220.2M
IPO Year
2015
1994

Fundamental Metrics

Financial Performance
Metric
VYGR
UIS
Price
$3.48
$3.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$16.50
$5.67
AVG Volume (30 Days)
568.1K
1.0M
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,135,000.00
$1,950,100,000.00
Revenue This Year
$34.04
N/A
Revenue Next Year
$7.92
$2.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.83
$1.97
52 Week High
$5.55
$4.98

Technical Indicators

Market Signals
Indicator
VYGR
UIS
Relative Strength Index (RSI) 43.51 56.90
Support Level $3.31 $3.51
Resistance Level $4.29 $4.06
Average True Range (ATR) 0.20 0.38
MACD -0.02 -0.07
Stochastic Oscillator 30.77 46.02

Price Performance

Historical Comparison
VYGR
UIS

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.

Share on Social Networks: